



RNS Number : 5401K
EKF Diagnostics Holdings PLC
22 December 2022

RNS Reach

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Point-of-Care update
Further innovation across established business

***Launch of hand-held lactate analyser for the veterinary market
following earlier launch of updated hand-held haemoglobin analyzer
with EKF Link digital connectivity***

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces further product innovation in its established Point-of-Care ("POC") business with the launch of [Lactate Scout Vet](#), a hand-held lactate analyzer designed specifically for POC testing in veterinary settings. This follows the launch of EKF's enhanced version of [DiaSpect Tm](#), in October 2022, with wireless connectivity powered by the newly released [EKF Link middleware](#), which allows POC test results to be centralised in one place and enables real-time remote management of data.

Lactate Scout Vet

Lactate Scout Vet uses the same proven technology that was initially developed to provide elite sports coaches and athletes with a precise and easy-to-use hand-held lactate test. Lactate Scout Vet has the ability to deliver accurate lactate measurements within 10 seconds, from just a 0.2 µL capillary blood sample, taken via earlobe prick. It has quick and easy species selection options and can store up to 500 results. Lactate Scout Vet is a user-friendly device, and the simple to navigate e-paper display provides excellent readability in varying light conditions, as well as at different viewing angles.

Lactate testing is increasingly used in the veterinary clinic for prognosis and diagnosis in a number of clinical presentations. It can be applied as a rapid triage and risk stratification tool assigning higher and lower risk categories. EKF's new Lactate Scout Vet provides validated results comparable to laboratory-based testing, allowing the veterinarian to obtain rapid, reliable

results at the POC and also helps to inform treatment decisions, while providing the opportunity to monitor whole blood lactate concentration in real-time.

DiaSpect Tm launched with secure POC connectivity

In October 2022, EKF launched a new version of DiaSpect Tm, now powered by EKF Link, enabling new functions like Hematocrit calculation, quality control management and patient data management functions. DiaSpect Tm delivers laboratory quality results in one second from the microcuvette being placed into the analyzer.

The haemoglobin analyzer is palm-sized, making it easily transportable, and ideal for use in any screening setting even in challenging climatic environments, and is now compatible with the new state-of-the-art POC data management platform.

Mike Salter, CEO, of EKF, said: *"With our vast experience in lactate measurement in the clinical diagnostics market, we are excited to launch our latest analyzer, Lactate Scout Vet, which is designed specifically for the veterinary market. We are already a well-established manufacturer, supplier, distributor and exporter globally of lactate analyzers, delivering dependable pre and post-sales support. We pride ourselves on developing easy-to-use devices that provide reliable, fast and accurate results."*

"Just a few weeks ago, our team successfully introduced our POC testing connectivity solutions at MEDICA trade conference, including the enhanced DiaSpect Tm hand-held haemoglobin analyser and the new EKF Link digital connectivity software, both of which were well received. It is great to see that we continue to make further progress on new product and new market initiatives."



EKF's Lactate Scout Vet hand-held analyzer



DiaSpect Tm powered by EKF Link - a hand-held hemoglobin analyzer

EKF Diagnostics Holdings plc
Mike Salter, CEO
Marc Davies, CFO

www.ekfdiagnostics.com
Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)
Aubrey Powell / George Tzimas / Oliver Platts

Tel: +44 (0)20 7496 3000

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams / Ben Farrow

Tel: +44 (0)20 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or
ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care	Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Central Laboratory	Clinical chemistry, small lab analysers <i>Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin</i>
Life Sciences	Small and large-scale enzyme fermentation, custom and contract manufactured products
Contract Manufacturing	Bulk formulation, sample collection kits, private labelling, molecular and forensic kits
Laboratory Testing	Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRATBBPTMTATBFT Anonymous (not verified) Point-of-Care update 33195109 A Thu, 12/22/2022 - 07:00 LSE RNS Company Announcement - General EKF